Leon F. Stankowski, Jr.
Senior Scientific Director, Genetic and In Vitro Toxicology
Dr. Leon F. Stankowski, Jr. is responsible for guiding research and development for new services in the Genetic and In Vitro Toxicology Department, and providing guidance on all aspects of genetic toxicology to help clients reach their goal of regulatory approval for new products. He also acts as a consultant to clients with a lack of genetic toxicology expertise or those who have encountered adverse genetic toxicology issues.
Dr. Stankowski, Jr. is active in the EMGS, GTA (past BOD, current treasurer), and the HESI Genetic Toxicology Technical Committee (past co-chair, current member of the Nitrosamine Workgroup and others). He is a member of various Expert Workgroups drafting/revising the OECD genotoxicity test guidelines, and CORESTA and other groups addressing the challenges of evaluating electronic and next generation nicotine delivery systems.
DAY 2: December 5th, 2024
SESSION: Validation of the Enhanced Ames Test for Nitrosamines
◆ Optimization of test conditions.
◆ Selection of positive controls.
◆ Collecting historical control data.
◆ Follow-up for positive or negative responses.
DAY 2: December 1st, 2023
SESSION: An update on the ongoing efforts to optimize the ames assay by the hesigttc mechanism-based genotoxicity risk assessment (MGRA) nitrosamine subgroup
◆ Workgroup members and organization.
◆ Key protocol features and rationale.
◆ Comparison of metabolic activation conditions and results to date.
